Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Selected publications

Poorebrahim, M, Sadeghi, S, Fakhr, E. Foad Abazari, M, Poortahmasebi, V, Kheirollahi, A, Askari, H, Rajabzadeh, A, Rastegarpanah, M, Linē, A & Angel Cid-Arregui (2019) Production of CAR T-cells by GMP-grade lentiviral vectors: Latest advances and future prospects. Crit Rev Clin Lab Sci. In press.

Junco JA, Rodriguez R, Fuentes F, Baladron I, Castro MD, Calzada L, Valenzuela C, Bover E, Pimentel E, Basulto R, Arteaga N, Cid-Arregui A et al. (2019) Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac. Front Oncol, 9: 49

Quandt, J, Schlude C, Bartoschek, M, Will, M, Cid-Arregui, A, Wiemann, S, Momburg, F, and Beckhove, P. (2018) Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. OncoImmunology, 7:12

Garcia DA, Abba MC, Castillo M, Briceño J, Aristizabal FA, Cid Arregui A (2017) Differential host DNA methylation patterns of low grade intraepithelial neoplasia and cervical cancer identified by genome-wide methylation profiling. Integr Mol Med, 4: 1-13

Juarez, V, Pasolli, H A, Hellwig, A,Garbi, N and Cid Arregui, A. Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. 2012. Open Virol J, Vol. 6:270-276.

Garcia-Chagollan M, Jave-Suarez LF, Haramati J, Sanchez-Hernandez PE, Aguilar-Lemarroy A, Bueno-Topete MR, Pereira-Suarez AL, Fafutis-Morris M, Cid-Arregui A, del Toro-Arreola S. Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1. J Biomed Sci. 2013 Aug 16;20:60.

Darnell, G.A., Schroder, W.S., Antalis, T.M., Lambley, E., Major, L., Gardner, J., Birrell, G., Cid-Arregui, A. and Suhrbier A. (2007) The accelerated degradation of the retinoblastoma protein mediated by human papillomavirus E7 requires the cysteine protease calpain. J BIol Chem 282:37492-37500.

Baez-Astua, A., E. Herraez-Hernandez, N. Garbi, H. A. Pasolli, V. Juarez, H. Zur Hausen, and A. Cid-Arregui (2005). Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 e7 proteins induces enhanced e7-specific antibody and cytotoxic T-cell responses J Virol. 79:12807-17.

Cid-Arregui, A., Juarez, V. and zur Hausen, H. (2003) A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol. 77:4928-37.

to top
powered by webEdition CMS